SNWV - SANUWAVE Health, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.388
-0.002 (-0.51%)
At close: 12:43PM EDT
Stock chart is not supported by your current browser
Previous Close0.390
Open0.396
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.380 - 0.400
52 Week Range0.090 - 0.640
Volume9,300
Avg. Volume116,012
Market Cap58.891M
Beta-2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.040
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    SANUWAVE Announces DFU Joint Investigational Partnership with HyperMed

    SANUWAVE Health, Inc. (SNWV) is pleased to announce a partnership with HyperMed in Memphis, TN to sponsor a continuing clinical investigation on Diabetic Foot Ulcers (DFUs).  This investigational work is expected to begin in August 2018.  An initial case series will be conducted at two sites, the primary site being the Vascular and Wound Care Center at University Hospital, Rutgers NJMS in Newark, NJ with Dr. Oscar Alvarez as the Principal Investigator, and the second site at Olive View-UCLA Medical Center with Dr. Aksone Nouvong leading the efforts. As a result of Dr. Alvarez’s leadership and case work, he will be able to provide SANWUAVE with valuable, measurable data to continue to expand our understanding of the dermaPACE® System’s mechanism of action.  Dr. Nouvong has already performed and published extensive research using the HyperView spectral imaging device.  These two renowned investigators and practitioners in wound care, with their combined expertise, will expand the already extensive clinical data associated with dermaPACE®.  Both researchers participated in previous dermaPACE® DFU trials.

  • GlobeNewswire24 days ago

    SANUWAVE Announces Third Quarter Attendance at Eight Medical Conferences

    SUWANEE, GA., June 28, 2018-- SANUWAVE Health, Inc. SANUWAVE is pleased to announce that since receiving clearance from the FDA in late December 2017, its presence has been increasing in the medical device ...

  • GlobeNewswire26 days ago

    SANUWAVE Signs MOU for Exclusive Joint Venture with FKS in Southeast Asia

    SANUWAVE Health, Inc. (SNWV) is pleased to announce a signed Joint Venture (JV) agreement with FKS, a JohnFK Medical company in Southeast Asia.  The first of two exclusivity fees have been received with a second scheduled for the third quarter 2018.  The Agreement will cover Taiwan, Singapore, Malaysia, Brunei, Cambodia, Myanmar, Laos, Thailand, Philippines, Indonesia and Vietnam.  The JV is expected to place at least 40 devices during 2018 and over 200 in the first three years, with the first shipments going out in the third quarter of 2018. The agreement is similar to other international JV’s entered into by SANUWAVE in that, the profits are shared equally among the partners, a management committee exists to ensure success of the JV, and exclusivity fees are involved to ensure mutual success.  The agreement also stipulates that one of SANUWAVE Health’s long-time science advisors, Dr. Wang, will be a consultant to the JV.

  • GlobeNewswire26 days ago

    Kevin Richardson, CEO of SANUWAVE Health, Inc., Returns to Uptick Newswire’s “Stock Day” with Marcus Heatherly

    The Company, which was a start-up research and development company is now moving into the commercialization phase.  SANUWAVE has continued to make strides on achieving its goal to treat every wound everywhere.  Most recently the Company confirmed a deal that will increase its international footprint into southeast Asia.

  • GlobeNewswire26 days ago

    SANUWAVE Signs Joint Venture Partnership with Tarbaca for 3 Countries in Central America

    SUWANEE, GA, June 26, 2018-- SANUWAVE Health, Inc. is excited to announce the execution of a binding term sheet for a Joint Venture with Tarbaca Lightning, the distribution company of Latin America Pharma ...

  • GlobeNewswire2 months ago

    SANUWAVE Hires Shri Parikh as President for Global Healthcare Division

    SANUWAVE Health, Inc. (SNWV) is excited to announce that Shri Parikh has joined SANUWAVE Health effective May 31, 2018 as President of our Healthcare division. Shri most recently joins us from Molnlycke Health Care where he held the title of Vice President, Sales and Marketing.

  • Zacks Small Cap Research2 months ago

    SNWV: Several Milestones in Q1 Including Initial U.S. dermaPACE Revenue

    Q1 ’18 marked a milestone for SNWV - or more accurately, marked three milestones. The $344k of revenue is the highest Q1 revenue in company history and it included U.S. dermaPACE revenue – which is another first. U.S. dermaPACE revenue relates to the first shipments to Premier Shockwave.

  • GlobeNewswire2 months ago

    SANUWAVE Health Reports First Quarter Financial Results and Provides a Business Update

    SUWANEE, Ga., May 16, 2018-- SANUWAVE Health, Inc. reported financial results for the three months ended March 31, 2018 with the SEC on Tuesday, May 15, 2018 and will provide a business update on a conference ...

  • GlobeNewswire2 months ago

    SANUWAVE Health to Hold First Quarter 2018 Financial Results and Business Update Call on Wednesday, May 16, 2018

    SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the first quarter ended March 31, 2018 shortly. The Company will host a conference call on Wednesday, May 16, 2018, beginning at 9:00AM Eastern Time to discuss the first quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.  SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration.

  • GlobeNewswire2 months ago

    Dr. Perry Mayer Joins SANUWAVE as Science Advisor to Clinical Advisory Board

    SANUWAVE Health, Inc. (SNWV) is pleased to announce that Dr. Perry Mayer, Medical Director and principal at The Mayer Institute “TMI” in Hamilton, Ontario, Canada, will be joining the Clinical Advisory Board at SANUWAVE. TMI is one of Canada's prominent Preventative Diabetic Foot Care, Advanced Wound Care and Diabetes Education clinics. Dr. Mayer and his team are strongly committed to advancing technologies and prevention practices at TMI, a center of excellence in the treatment of the diabetic foot.

  • GlobeNewswire2 months ago

    SANUWAVE Announces AMBIENSYS SRL as Distributor for dermaPACE® in Romania

    Globally, AMBIENSYS SRL is known as a service provider in the areas of consulting, training in European funding, project management and implementation. AMBIENSYS SRL strives to provide clients with comprehensive information and services on funding opportunities, funding preparation, training and technical assistance during project implementation. AMBIENSYS SRL’s intent is to contribute to commercialization strength locally and regionally to sustainable innovations like the dermaPACE® System.

  • GlobeNewswire3 months ago

    SANUWAVE joins MenaCare as Territory Sales Manager for Sourcing and Screening of Potential Partners and Access to Clinical Trial Participation in the Middle East

    SUWANEE, GA, April 25, 2018-- SANUWAVE Health, Inc. is pleased to announce that the company will join MenaCare as the Territory Sales Manager for sourcing and screening of potential distributors and access ...

  • Zacks Small Cap Research3 months ago

    SNWV: Q4 Results, Operational Update: OUS Sales Finally Rebound, Initial U.S. Revenue Expected Q1

    With the U.S. strategy firming up, including initial distribution through Premier Shockwave (targeting VA and Indian Health) and initiation of various clinical (marketing-focused) clinical studies, SNWV is wasting no time in capitalizing on the domestic opportunity. Management expects revenue contribution from the U.S. as early as Q1 – and (mostly) depending on initial rates of VA-related adoption and utilization as well as (likely more incremental) OVA (i.e.

  • ACCESSWIRE5 months ago

    Independent Research on Trending Growth Companies: Northwest Biotherapeutics and Sanuwave Health

    NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Northwest Biotherapeutics, Inc. (OTCQB: NWBO) and Sanuwave Health ...